Roche Czech Republic made a net profit of CZK 252 mil in 2016, up 394% compared to the previous year. Total sales reached CZK 4,962 mil, which is down 8.88% when compared to the previous year.
Historically, between 2003 and 2016, the company’s net profit reached a high of CZK 252 mil in 2016 and a low of CZK 3.04 mil in 2003. Over the last decade the firm's net profit increased by an average of 23.2% a year.
Sales have grown by 4.25% a year on average since 2006. They reached a high of CZK 5,445 mil in 2015 and a low of CZK 2,418 mil in 2003.
The company has been operating with an average EBITDA margin of 6.07% in the last 5 years and average net margin of 2.34%. The firm generated an average return on invested capital of 6.60% for its shareholders over the last five years.
As far as Roche Czech Republic's peers are concerned, Pfizer Czech Republic posted a net profit and sales of CZK 73.4 mil and CZK 3,243 mil in 2016, Bayer Czech Republic generated a net profit of CZK 175 mil (with sales of CZK 4,326 mil), and Amgen Czech Republic netted USD CZK 31.5 mil (sales of CZK 626 mil).
You can see all the company’s data at Roche Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
